PEDIATRIC ONCOLOGY GROUP

儿科肿瘤组

• 批准号: 6588181
• 负责人: GREGORY H REAMAN
• 金额: $ 858.74万
• 依托单位: NATIONAL CHILDHOOD CANCER FOUNDATION
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-07-01 至 2003-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6588181
• 关键词: 6 thiopurine; Ewing's tumor; Hodgkin's disease; Wilms' tumor; XomaZyme; acivicin; acute leukemia; acute lymphocytic leukemia; acute myelogenous leukemia; adolescence (12-20); antineoplastics; asparaginase; astrocytoma; biological response modifiers; bone marrow transplantation; brain neoplasms; cancer registry /resource; cancer risk; central nervous system neoplasms; child (0-11); chronic myelogenous leukemia; cis platinum compound; clinical research; clinical trial phase I; colony stimulating factor; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; cyclosporines; cytosine arabinoside; daunorubicin; deferoxamine; deoxycoformycin; doxorubicin; drug screening /evaluation; enalapril; ependymoma; etoposide; fazarabine; fluorouracil; germ cell neoplasms; glioma; hepatoblastoma; hepatocellular carcinoma; human genetic material tag; human immunodeficiency virus 1; human subject; human therapy evaluation; human tissue; ifosfamide; interferons; interleukin 2; medulloblastoma; melphalan; metastasis; methotrexate; mitoxantrone; molecular oncology; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer relapse /recurrence; neoplasm /cancer surgery; neuroblastoma; nonHodgkin's lymphoma; osteosarcoma; paclitaxel; pediatric neoplasm /cancer; pediatric pharmacology; podophyllin; prednisone; retinoate; rhabdomyosarcoma; tissue resource /registry; topotecan; trimetrexate; vincristine

The Pediatric Oncology Group (POG) is a multi-institutional, multidisciplinary cooperative Group whose goal is to control cancer among children and adolescents by therapeutic research aimed at improving the survival and quality of life. The 101 institutions and 1,906 individual members of POG pool their knowledge and resources to jointly develop and conduct a wide variety of large-scale clinical and laboratory studies. Member investigators include pediatric oncologists, pathologists, surgeons, radiation therapists, diagnostic radiologists, statisticians, clinical research assistants, oncology nurse specialists, and others who cooperate to improve the outcomes of treatment and better understand the biology of childhood cancer. Reference laboratories conduct an array of adjunct studies of biologic samples for genetic, molecular, and cellular characteristics with subsequent correlation of biologic features with patient characteristics and outcome, providing unique opportunities to address scientific questions relating to risk assessment, epidemiology, pathobiology and other cancer-related topics. The overall aims of this five-year renewal application are to increase cure rates of all forms of childhood cancer while simultaneously reducing the acute and late consequences of treatment by design of risk-based therapies. We also aim to increase accruals, reduce barriers to enrollment, improve long-term follow-up, and extend the benefits of clinical trials participation. Traditional outcome analyses and translational research will be supplemented by innovative studies of alternative endpoints, including costs and quality of life. The Operations Office is the central Group headquarters and provides the staff and support for the overall scientific, administrative, and fiscal management of the Group. The Operations Office functions include responsibilities for all interactions with NCI, review of individual and institutional membership status and performance, maintenance of the Group bibliography, responsibility for convening and conducting semiannual meetings, distribution of monthly mailings and minutes, oversight of quality control and institutional audits, responsibility for preparation and coordination of all protocols from concept/LOI through activation and revisions and amendments as necessary, and provision of logistical and financial support to scientific committees, and disbursement of third party payments where relevant for participants without cooperative agreements from NCI. In all aspects of general scientific oversight and development of research plans and analyses for each disease studied, the Operations Office works closely with the Statistical Office in a seamless coordination of effort. This application requests renewed and continued ending for the Operations Office and for the scientific committees, reference laboratories and key personnel of the Group.

儿科肿瘤组（POG）是一个多机构， 多学科合作小组，其目标是控制癌症， 儿童和青少年的治疗研究，旨在改善 生存和生活质量。101个机构和1 906名个人 POG成员汇集他们的知识和资源，共同开发和 进行各种大规模的临床和实验室研究。 成员研究者包括儿科肿瘤学家，病理学家， 外科医生，放射治疗师，诊断放射科医生，统计学家， 临床研究助理，肿瘤学护士专家，以及其他 合作以改善治疗结果，并更好地了解 儿童癌症的生物学参考实验室进行一系列 生物样本的遗传、分子和细胞辅助研究 生物学特征与随后的相关性 患者特征和结果，提供独特的机会， 解决与风险评估、流行病学 病理生物学和其他癌症相关的主题。 五年延期申请的总体目标是增加 所有形式的儿童癌症的治愈率，同时减少 基于风险的设计治疗的急性和晚期后果 治疗我们还旨在增加应计利润，减少 入组，改善长期随访，并延长 参与临床试验。 传统的结果分析和 翻译研究将得到以下创新研究的补充： 替代终点，包括成本和生活质量。 运营办公室是集团的中央总部， 为整体科学、行政和财政提供人员和支持 管理本集团。 行动处的职能包括 负责与NCI的所有互动，审查个人和 机构成员地位和业绩，小组的维持 书目，负责召集和进行半年一次的 会议、每月邮件和会议记录的分发、 质量控制和机构审计，编制责任 从概念/LOI到激活的所有协议的协调， 必要时进行修订和修正， 对科学委员会的财政支持，以及第三次 与无合作社参与人相关的当事方付款 NCI的协议。在一般科学监督的所有方面， 为每种研究疾病制定研究计划和分析， 行动处与统计处紧密合作， 协调努力。 本申请要求更新和继续结束作业 科学委员会、参考实验室和重点实验室 集团的人员。

项目成果

Lymphocyte predominant Hodgkin disease: clinico-pathologic features and results of treatment--the Pediatric Oncology Group experience.

淋巴细胞为主型霍奇金病：临床病理特征和治疗结果——儿科肿瘤学小组的经验。

• DOI: 10.1002/(sici)1096-911x(199712)29:6
• 发表时间: 1997
• 期刊: Medical and pediatric oncology
• 作者: Karayalcin,G;Behm,FG;Gieser,PW;Kung,F;Weiner,M;Tebbi,CK;Ferree,C;Marcus,R;Constine,L;Mendenhall,NP;Chauvenet,A;Murphy,SB
• 通讯作者: Murphy,SB

Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study.

氮芥、长春新碱、丙卡巴肼和泼尼松作为辅助化疗治疗髓母细胞瘤。

• DOI: 10.3171/jns.1991.74.6.0905
• 发表时间: 1991
• 期刊: Journal of neurosurgery
• 影响因子: 4.1
• 作者: Krischer,JP;Ragab,AH;Kun,L;Kim,TH;Laurent,JP;Boyett,JM;Cornell,CJ;Link,M;Luthy,AR;Camitta,B
• 通讯作者: Camitta,B

The t(10;14)(q24;q11) of T-cell acute lymphoblastic leukemia juxtaposes the delta T-cell receptor with TCL3, a conserved and activated locus at 10q24.

T 细胞急性淋巴细胞白血病的 t(10;14)(q24;q11) 将 delta T 细胞受体与 TCL3（10q24 上的保守且激活的位点）并置。

• DOI: 10.1073/pnas.87.8.3161
• 发表时间: 1990
• 期刊: Proceedings of the National Academy of Sciences of the United States of America
• 影响因子: 11.1
• 作者: Zutter,M;Hockett,RD;Roberts,CW;McGuire,EA;Bloomstone,J;Morton,CC;Deaven,LL;Crist,WM;Carroll,AJ;Korsmeyer,SJ
• 通讯作者: Korsmeyer,SJ

Pediatric orofacial and laryngopharyngeal rhabdomyosarcoma. An Intergroup Rhabdomyosarcoma Study report.

小儿口面部和喉咽横纹肌肉瘤。

• DOI: 10.1001/archotol.1987.01860110091014
• 发表时间: 1987
• 期刊: Archives of otolaryngology--head & neck surgery
• 作者: Wharam,MD;Beltangady,MS;Heyn,RM;Lawrence,W;RaneyJr,RB;Ruymann,FB;Soule,EH;Tefft,M;Maurer,HM
• 通讯作者: Maurer,HM

Rhabdomyosarcoma in children and adolescents. A review.

儿童和青少年的横纹肌肉瘤。

• 发表时间: 1987
• 期刊: Hematology/oncology clinics of North America
• 作者: Ruymann,FB